Cargando…

α1AMP-Activated Protein Kinase Protects against Lipopolysaccharide-Induced Endothelial Barrier Disruption via Junctional Reinforcement and Activation of the p38 MAPK/HSP27 Pathway

Vascular hyperpermeability is a determinant factor in the pathophysiology of sepsis. While, AMP-activated protein kinase (AMPK) is known to play a role in maintaining endothelial barrier function in this condition. Therefore, we investigated the underlying molecular mechanisms of this protective eff...

Descripción completa

Detalles Bibliográficos
Autores principales: Angé, Marine, Castanares-Zapatero, Diego, De Poortere, Julien, Dufeys, Cécile, Courtoy, Guillaume E., Bouzin, Caroline, Quarck, Rozenn, Bertrand, Luc, Beauloye, Christophe, Horman, Sandrine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7432762/
https://www.ncbi.nlm.nih.gov/pubmed/32759774
http://dx.doi.org/10.3390/ijms21155581
_version_ 1783571868906684416
author Angé, Marine
Castanares-Zapatero, Diego
De Poortere, Julien
Dufeys, Cécile
Courtoy, Guillaume E.
Bouzin, Caroline
Quarck, Rozenn
Bertrand, Luc
Beauloye, Christophe
Horman, Sandrine
author_facet Angé, Marine
Castanares-Zapatero, Diego
De Poortere, Julien
Dufeys, Cécile
Courtoy, Guillaume E.
Bouzin, Caroline
Quarck, Rozenn
Bertrand, Luc
Beauloye, Christophe
Horman, Sandrine
author_sort Angé, Marine
collection PubMed
description Vascular hyperpermeability is a determinant factor in the pathophysiology of sepsis. While, AMP-activated protein kinase (AMPK) is known to play a role in maintaining endothelial barrier function in this condition. Therefore, we investigated the underlying molecular mechanisms of this protective effect. α1AMPK expression and/or activity was modulated in human dermal microvascular endothelial cells using either α1AMPK-targeting small interfering RNA or the direct pharmacological AMPK activator 991, prior to lipopolysaccharide (LPS) treatment. Western blotting was used to analyze the expression and/or phosphorylation of proteins that compose cellular junctions (zonula occludens-1 (ZO-1), vascular endothelial cadherin (VE-Cad), connexin 43 (Cx43)) or that regulate actin cytoskeleton (p38 MAPK; heat shock protein 27 (HSP27)). Functional endothelial permeability was assessed by in vitro Transwell assays, and quantification of cellular junctions in the plasma membrane was assessed by immunofluorescence. Actin cytoskeleton remodeling was evaluated through actin fluorescent staining. We consequently demonstrate that α1AMPK deficiency is associated with reduced expression of CX43, ZO-1, and VE-Cad, and that the drastic loss of CX43 is likely responsible for the subsequent decreased expression and localization of ZO-1 and VE-Cad in the plasma membrane. Moreover, α1AMPK activation by 991 protects against LPS-induced endothelial barrier disruption by reinforcing cortical actin cytoskeleton. This is due to a mechanism that involves the phosphorylation of p38 MAPK and HSP27, which is nonetheless independent of the small GTPase Rac1. This results in a drastic decrease of LPS-induced hyperpermeability. We conclude that α1AMPK activators that are suitable for clinical use may provide a specific therapeutic intervention that limits sepsis-induced vascular leakage.
format Online
Article
Text
id pubmed-7432762
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-74327622020-08-27 α1AMP-Activated Protein Kinase Protects against Lipopolysaccharide-Induced Endothelial Barrier Disruption via Junctional Reinforcement and Activation of the p38 MAPK/HSP27 Pathway Angé, Marine Castanares-Zapatero, Diego De Poortere, Julien Dufeys, Cécile Courtoy, Guillaume E. Bouzin, Caroline Quarck, Rozenn Bertrand, Luc Beauloye, Christophe Horman, Sandrine Int J Mol Sci Article Vascular hyperpermeability is a determinant factor in the pathophysiology of sepsis. While, AMP-activated protein kinase (AMPK) is known to play a role in maintaining endothelial barrier function in this condition. Therefore, we investigated the underlying molecular mechanisms of this protective effect. α1AMPK expression and/or activity was modulated in human dermal microvascular endothelial cells using either α1AMPK-targeting small interfering RNA or the direct pharmacological AMPK activator 991, prior to lipopolysaccharide (LPS) treatment. Western blotting was used to analyze the expression and/or phosphorylation of proteins that compose cellular junctions (zonula occludens-1 (ZO-1), vascular endothelial cadherin (VE-Cad), connexin 43 (Cx43)) or that regulate actin cytoskeleton (p38 MAPK; heat shock protein 27 (HSP27)). Functional endothelial permeability was assessed by in vitro Transwell assays, and quantification of cellular junctions in the plasma membrane was assessed by immunofluorescence. Actin cytoskeleton remodeling was evaluated through actin fluorescent staining. We consequently demonstrate that α1AMPK deficiency is associated with reduced expression of CX43, ZO-1, and VE-Cad, and that the drastic loss of CX43 is likely responsible for the subsequent decreased expression and localization of ZO-1 and VE-Cad in the plasma membrane. Moreover, α1AMPK activation by 991 protects against LPS-induced endothelial barrier disruption by reinforcing cortical actin cytoskeleton. This is due to a mechanism that involves the phosphorylation of p38 MAPK and HSP27, which is nonetheless independent of the small GTPase Rac1. This results in a drastic decrease of LPS-induced hyperpermeability. We conclude that α1AMPK activators that are suitable for clinical use may provide a specific therapeutic intervention that limits sepsis-induced vascular leakage. MDPI 2020-08-04 /pmc/articles/PMC7432762/ /pubmed/32759774 http://dx.doi.org/10.3390/ijms21155581 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Angé, Marine
Castanares-Zapatero, Diego
De Poortere, Julien
Dufeys, Cécile
Courtoy, Guillaume E.
Bouzin, Caroline
Quarck, Rozenn
Bertrand, Luc
Beauloye, Christophe
Horman, Sandrine
α1AMP-Activated Protein Kinase Protects against Lipopolysaccharide-Induced Endothelial Barrier Disruption via Junctional Reinforcement and Activation of the p38 MAPK/HSP27 Pathway
title α1AMP-Activated Protein Kinase Protects against Lipopolysaccharide-Induced Endothelial Barrier Disruption via Junctional Reinforcement and Activation of the p38 MAPK/HSP27 Pathway
title_full α1AMP-Activated Protein Kinase Protects against Lipopolysaccharide-Induced Endothelial Barrier Disruption via Junctional Reinforcement and Activation of the p38 MAPK/HSP27 Pathway
title_fullStr α1AMP-Activated Protein Kinase Protects against Lipopolysaccharide-Induced Endothelial Barrier Disruption via Junctional Reinforcement and Activation of the p38 MAPK/HSP27 Pathway
title_full_unstemmed α1AMP-Activated Protein Kinase Protects against Lipopolysaccharide-Induced Endothelial Barrier Disruption via Junctional Reinforcement and Activation of the p38 MAPK/HSP27 Pathway
title_short α1AMP-Activated Protein Kinase Protects against Lipopolysaccharide-Induced Endothelial Barrier Disruption via Junctional Reinforcement and Activation of the p38 MAPK/HSP27 Pathway
title_sort α1amp-activated protein kinase protects against lipopolysaccharide-induced endothelial barrier disruption via junctional reinforcement and activation of the p38 mapk/hsp27 pathway
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7432762/
https://www.ncbi.nlm.nih.gov/pubmed/32759774
http://dx.doi.org/10.3390/ijms21155581
work_keys_str_mv AT angemarine a1ampactivatedproteinkinaseprotectsagainstlipopolysaccharideinducedendothelialbarrierdisruptionviajunctionalreinforcementandactivationofthep38mapkhsp27pathway
AT castanareszapaterodiego a1ampactivatedproteinkinaseprotectsagainstlipopolysaccharideinducedendothelialbarrierdisruptionviajunctionalreinforcementandactivationofthep38mapkhsp27pathway
AT depoorterejulien a1ampactivatedproteinkinaseprotectsagainstlipopolysaccharideinducedendothelialbarrierdisruptionviajunctionalreinforcementandactivationofthep38mapkhsp27pathway
AT dufeyscecile a1ampactivatedproteinkinaseprotectsagainstlipopolysaccharideinducedendothelialbarrierdisruptionviajunctionalreinforcementandactivationofthep38mapkhsp27pathway
AT courtoyguillaumee a1ampactivatedproteinkinaseprotectsagainstlipopolysaccharideinducedendothelialbarrierdisruptionviajunctionalreinforcementandactivationofthep38mapkhsp27pathway
AT bouzincaroline a1ampactivatedproteinkinaseprotectsagainstlipopolysaccharideinducedendothelialbarrierdisruptionviajunctionalreinforcementandactivationofthep38mapkhsp27pathway
AT quarckrozenn a1ampactivatedproteinkinaseprotectsagainstlipopolysaccharideinducedendothelialbarrierdisruptionviajunctionalreinforcementandactivationofthep38mapkhsp27pathway
AT bertrandluc a1ampactivatedproteinkinaseprotectsagainstlipopolysaccharideinducedendothelialbarrierdisruptionviajunctionalreinforcementandactivationofthep38mapkhsp27pathway
AT beauloyechristophe a1ampactivatedproteinkinaseprotectsagainstlipopolysaccharideinducedendothelialbarrierdisruptionviajunctionalreinforcementandactivationofthep38mapkhsp27pathway
AT hormansandrine a1ampactivatedproteinkinaseprotectsagainstlipopolysaccharideinducedendothelialbarrierdisruptionviajunctionalreinforcementandactivationofthep38mapkhsp27pathway